Related Experiment Video
Updated: Apr 28, 2026

Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
Integrated analysis reveals microbiota-metabolite-immune alterations associated with coronary heart disease
Baoquan Ren1, Hong Wang1, Yanyan Cao1
1Cardiac Care Unit, Qinhuangdao Integrated Traditional Chinese and Western Medicine Hospital, Qinhuangdao, Hebei, China.
Insights
Coronary heart disease (CHD) is linked to gut microbiota changes and reduced microbial diversity. Elevated phenylacetylglutamine (PAGln) in CHD patients may impact immune function, suggesting a connection between gut health and heart disease.
Area of Science:
- Microbiology
- Immunology
- Cardiovascular Medicine
Background:
- The interplay between gut microbiota, metabolites, immune system, and coronary heart disease (CHD) is not fully understood.
- Gut dysbiosis and its impact on immune homeostasis in CHD require further investigation.
Purpose of the Study:
- To investigate the relationship between gut microbiota composition, specific metabolites (TMAO and PAGln), and immune cell subsets in patients with CHD.
- To explore potential correlations between gut microbial alterations, metabolite levels, and CHD severity.
Main Methods:
- 16S rRNA gene sequencing for gut microbiota analysis.
- Mass spectrometry for quantifying plasma trimethylamine N-oxide (TMAO) and phenylacetylglutamine (PAGln).
- Flow cytometry for assessing T, B, and NK lymphocyte subsets; PICRUSt2 for predicting microbial functions.
Main Results:
- CHD patients exhibited reduced gut microbial richness and altered microbial composition compared to controls.
- Plasma PAGln levels were significantly higher in CHD patients, particularly those with acute coronary syndrome (ACS), and correlated positively with CHD severity.
- PAGln levels negatively correlated with total lymphocytes, T cells, and B cells, suggesting an impact on immune status.
Conclusions:
- CHD is associated with gut microbiota dysbiosis and reduced microbial richness.
- Alterations in gut microbiota and elevated PAGln may contribute to immune dysregulation in CHD.
- These findings highlight the gut microbiome as a potential factor influencing immune homeostasis in coronary heart disease.
Background:
The relationship between gut microbiota, metabolites, immune environment, and coronary heart disease (CHD) remains incompletely understood.
Methods:
This study enrolled 100 non-CHD controls and 302 CHD patients, including 102 with acute coronary syndrome (ACS), 100 with chronic stable angina pectoris (CSAP), and 100 with ischemic cardiomyopathy (ICM). Gut microbiota was analyzed via 16S rRNA gene sequencing, plasma trimethylamine N-oxide (TMAO) and phenylacetylglutamine (PAGln) were measured by mass spectrometry, and flow cytometry was used to assess T, B, and natural killer (NK) lymphocyte subsets.
Results:
CHD patients showed reduced gut microbial richness (Chao1 and ACE indices, p < 0.05) compared to controls, with enriched Actinomycetaceae, Streptococcaceae, Rothia Micrococcaceae, Bacilli, Dialister in CHD groups. Predicted microbial functional pathways, including glutathione metabolism, nitrogen metabolism, and porphyrin and chlorophyll metabolism, were significantly reduced in CHD patients based on PICRUSt2 analysis. PAGln levels were significantly higher in CHD especially in ACS patients than in controls (p = 0.0016), positively correlating with CHD severity (GRACE score, Spearman r = 0.243, p < 0.001), while TMAO showed no significant difference. PAGln negatively correlated with total lymphocytes, T cells, and B cells, and was associated with altered abundances of Parabacteroides, Tannerellaceae, Bacilli, and so on.
Conclusion:
CHD is associated with gut microbiota dysbiosis, and reduced microbial richness, which may influence immune homeostasis.
Related Concept Videos
The Oral Microbiota
Functions of the Gut Microbiota
Gut-Brain Axis
Introduction to the Human Microbiota
Coronary Artery Disease I: Introduction
Microbiota of the Large Intestine
